1
|
Arantes LH, Crawford J, Gascon P, Latymer M, Launay-Vacher V, Rolland C, Scotte F, Wish J. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Crit Rev Oncol Hematol 2018; 129:79-90. [PMID: 30097240 DOI: 10.1016/j.critrevonc.2018.06.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Accepted: 06/13/2018] [Indexed: 12/12/2022] Open
Abstract
Erythropoiesis-stimulating agents (ESAs) are man-made forms of erythropoietin used in the treatment of anemia. This quick-scoping review of systematic literature reviews (SLRs) was conducted to define the clinical, economic, and health-related quality of life (HRQoL) outcomes for short-acting and long-acting ESAs in patients with chronic kidney disease-induced anemia (CKD-IA) and patients with chemotherapy-induced anemia (CIA). Embase, Medline, and the Cochrane Database of Systematic Reviews were searched from their establishment until October 2017. SLRs related to the use of short-acting and long-acting ESAs in the treatment of CIA and CKD-IA were included. Forty-eight studies met the inclusion criteria. The evidence suggests little difference in efficacy, HRQoL, and safety outcomes among ESA types. Cost-effectiveness and market price are likely to become determining factors driving the choice of agent. Comparative studies and costing models accounting for the utilization of biosimilars are needed to establish which ESAs are more cost-effective.
Collapse
Affiliation(s)
| | - Jeffrey Crawford
- Department of Hematology-Oncology, Duke University Medical Center, Durham, NC, USA
| | - Pere Gascon
- Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
| | | | | | | | - Florian Scotte
- Medical Oncology and Supportive Care Department, Hospital Foch, Suresnes, France
| | - Jay Wish
- Indiana University Health, Indianapolis, IN, USA
| |
Collapse
|
2
|
Robles NR. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 2016; 36:421-31. [PMID: 26894799 DOI: 10.1007/s40261-016-0378-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Chronic kidney disease (CKD) anemia treatment was revolutionized in the late 1980s with the introduction of recombinant human erythropoietin. This and related erythropoiesis-stimulating agents (ESAs) greatly benefited patients by decreasing debilitating symptoms, improving their quality of life, and freeing them from dependence on blood transfusions with their associated complications such as infections, sensitization impeding transplantation, and secondary iron overload. However, even in the initial studies, untoward effects were noted in patients receiving ESAs, including worsening hypertension, seizures, and dialysis access clotting. Later, increased mortality, malignancy progression and even stroke were reported in renal patients. This review focuses on the safety issues of ESAs in CKD patients.
Collapse
Affiliation(s)
- Nicolas Roberto Robles
- Cardiovascular Risk Institute, Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain. .,Unidad de Hipertensión Arterial, Hospital Infanta Cristina, Carretera de Portugal s/n, 06070, Badajoz, Spain.
| |
Collapse
|
3
|
Robles Perez-Monteoliva NR. [Erythropoietin, chronic renal failure and cancer]. Med Clin (Barc) 2016; 146:539-40. [PMID: 26832198 DOI: 10.1016/j.medcli.2015.12.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Revised: 12/06/2015] [Accepted: 12/09/2015] [Indexed: 11/27/2022]
|
4
|
Wauters I, Vansteenkiste J. Erythropoiesis-stimulating agents in cancer patients: reflections on safety. Expert Rev Clin Pharmacol 2014; 4:467-76. [DOI: 10.1586/ecp.11.22] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
5
|
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; 12:CD003407. [PMID: 23235597 PMCID: PMC8145276 DOI: 10.1002/14651858.cd003407.pub5] [Citation(s) in RCA: 101] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant human erythropoiesis stimulating agents (ESAs) and red blood cell transfusions. OBJECTIVES To assess the effects of ESAs to either prevent or treat anaemia in cancer patients. SEARCH METHODS This is an update of a Cochrane review first published in 2004. We searched the Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE and other databases. Searches were done for the periods 01/1985 to 12/2001 for the first review, 1/2002 to 04/2005 for the first update and to November 2011 for the current update. We also contacted experts in the field and pharmaceutical companies. SELECTION CRITERIA Randomised controlled trials on managing anaemia in cancer patients receiving or not receiving anti-cancer therapy that compared the use of ESAs (plus transfusion if needed). DATA COLLECTION AND ANALYSIS Several review authors assessed trial quality and extracted data. One review author assessed quality assessment and extracted data, a second review author checked for correctness. MAIN RESULTS This update of the systematic review includes a total of 91 trials with 20,102 participants. Use of ESAs significantly reduced the relative risk of red blood cell transfusions (risk ratio (RR) 0.65; 95% confidence interval (CI) 0.62 to 0.68, 70 trials, N = 16,093). On average, participants in the ESAs group received one unit of blood less than the control group (mean difference (MD) -0.98; 95% CI -1.17 to -0.78, 19 trials, N = 4,715). Haematological response was observed more often in participants receiving ESAs (RR 3.93; 95% CI 3.10 to 3.71, 31 trials, N = 6,413). There was suggestive evidence that ESAs may improve Quality of Life (QoL). There was strong evidence that ESAs increase mortality during active study period (hazard ratio (HR) 1.17; 95% CI 1.06 to 1.29, 70 trials, N = 15,935) and some evidence that ESAs decrease overall survival (HR 1.05; 95% CI 1.00 to 1.11, 78 trials, N = 19,003). The risk ratio for thromboembolic complications was increased in patients receiving ESAs compared to controls (RR 1.52, 95% CI 1.34 to 1.74; 57 trials, N = 15,498). ESAs may also increase the risk for hypertension (fixed-effect model: RR 1.30; 95% CI 1.08 to 1.56; random-effects model: RR 1.12; 95% CI 0.94 to 1.33, 31 trials, N = 7,228) and thrombocytopenia/haemorrhage (RR 1.21; 95% CI 1.04 to 1.42; 21 trials, N = 4,507). There was insufficient evidence to support an effect of ESA on tumour response (fixed-effect RR 1.02; 95% CI 0.98 to 1.06, 15 trials, N = 5,012). AUTHORS' CONCLUSIONS ESAs reduce the need for red blood cell transfusions but increase the risk for thromboembolic events and deaths. There is suggestive evidence that ESAs may improve QoL. Whether and how ESAs affects tumour control remains uncertain. The increased risk of death and thromboembolic events should be balanced against the potential benefits of ESA treatment taking into account each patient's clinical circumstances and preferences. More data are needed for the effect of these drugs on quality of life and tumour progression. Further research is needed to clarify cellular and molecular mechanisms and pathways of the effects of ESAs on thrombogenesis and their potential effects on tumour growth.
Collapse
Affiliation(s)
- Thomy Tonia
- University of BernInstitute of Social and Preventive MedicineBernSwitzerland3012
| | - Annette Mettler
- University of BernInstitute of Social and Preventive MedicineBernSwitzerland3012
| | - Nadège Robert
- Kantonsspitalapotheke WinterthurPharmacyBrauerstrasse 15WinterthurSwitzerlandCH‐8400
| | - Guido Schwarzer
- Institute of Medical Biometry and Medical Informatics, University Medical Center FreiburgGerman Cochrane CentreStefan‐Meier‐Str. 26FreiburgGermanyD‐79104
| | - Jerome Seidenfeld
- American Society of Clinical OncologyDepartment of Quality and Guidelines1900 Duke Street, Suite 200AlexandriaVAUSA22314
| | | | - Chris Hyde
- University of Exeter Medical School, University of ExeterPeninsula Technology Assessment Group (PenTAG)Veysey BuildingSalmon Pool LaneExeterUKEX2 4SG
| | - Andreas Engert
- University Hospital of CologneCochrane Haematological Malignancies Group, Department I of Internal MedicineKerpener Str. 62CologneGermany50924
| | - Julia Bohlius
- University of BernInstitute of Social and Preventive MedicineBernSwitzerland3012
| | | |
Collapse
|
6
|
Wauters I, Vansteenkiste J. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy. Expert Rev Anticancer Ther 2012; 12:1383-90. [PMID: 23113603 DOI: 10.1586/era.12.117] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
For years, the treatment of chemotherapy-induced anemia (CIA) consisted of red blood cell transfusions. Major disadvantages of transfusions are their temporary effect and limitation to treatment of severe anemia. In an extensive clinical trial program in patients with CIA, darbepoetin alfa (DA) - a long-acting recombinant human erythropoietin - was proven to be very effective in reducing transfusion needs in patients developing CIA. The administration is suitable with most chemotherapy schemes. Caution is needed in patients with a history of thrombo-embolic events, as a slightly higher incidence of these events is noted in patients treated with darbepoetin alfa or erythropoietin substitution agents (ESAs) in general. In recent years, concerns have been raised about a potential negative influence of these agents on survival. In this respect, it is important to make the distinction between studies on the treatment of existing CIA versus treatment with ESAs outside this indication. On the other hand, it has always been assumed that transfusions were a completely safe treatment, but concerns about a potential negative effect on survival have been raised for transfusions as well. The safety concerns with DA and ESAs in general led to a pharmacovigilance program and an adaptation of the guidelines for treatment of CIA, focusing on treatment of moderate CIA but no longer on mild CIA. Now that the most recent safety data of the pharmacovigilance program of ESAs is almost completed, the clinical impact of the shift to the treatment of only moderate anemia is discussed in this review, which provides a critical view on the indications of DA and the benefit-risk assessment, in order to provide good supportive care without harm to the patient.
Collapse
Affiliation(s)
- Isabelle Wauters
- Respiratory Oncology Unit (Pulmonology) and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium
| | | |
Collapse
|
7
|
Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PBV, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I. Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. Cancer 2012; 119:107-14. [DOI: 10.1002/cncr.27686] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2012] [Revised: 04/05/2012] [Accepted: 04/16/2012] [Indexed: 01/19/2023]
|
8
|
Hedenus M, Osterborg A, Tomita D, Bohac C, Coiffier B. Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis. Leuk Lymphoma 2012; 53:2151-8. [PMID: 22497574 PMCID: PMC3490475 DOI: 10.3109/10428194.2012.684347] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Erythropoiesis-stimulating agents (ESAs) are approved to treat anemia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. ESAs reduce transfusion rates, but some clinical studies suggest that ESAs may reduce survival or increase disease progression. This study-level meta-analysis examined the effects of darbepoetin alfa, epoetin alfa or epoetin beta on mortality, disease progression and transfusion incidence in patients with lymphoproliferative malignancies, using randomized, controlled trials of patients receiving chemotherapy and ESAs or standard of care. The odds ratio (OR) for mortality was 1.04 (95% confidence interval [CI], 0.81-1.34, random-effects model, 10 studies); the risk difference was - 0.01 (95% CI, - 0.03-0.02). The OR for disease progression was 1.02 (95% CI 0.81-1.30, random-effects model, five studies). A lower proportion of ESA-treated patients than controls received transfusions (seven studies). In this meta-analysis, ESAs reduced transfusions with no clear effect on mortality or disease progression in patients with lymphoproliferative malignancies receiving chemotherapy.
Collapse
|
9
|
Tonia T, Bohlius J. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients. Cancer Treat Res 2011; 157:217-238. [PMID: 21052959 DOI: 10.1007/978-1-4419-7073-2_13] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUND Since erythropoiesis-stimulating agents (ESAs) were licensed in 1993, more than 70 randomized controlled trials and more than 20 meta-analyses and systematic reviews on their effectiveness were conducted. Here, we present a systematic review on the meta-analyses of trials evaluating ESAs in cancer patients. METHODS We included all published meta-analyses of at least five randomized controlled trials that evaluated the effects of ESAs versus control in patients with any type of cancer or myelodysplastic syndrome. RESULTS We included a total of 23 systematic reviews and meta-analyses (16 literature based and 7 based on individual patient data (IPD)) that assessed several outcomes. All 12 meta-analyses reporting on transfusion risks demonstrated that ESAs significantly reduce the risk of transfusions. Eleven meta-analyses (nine based on published data and two on IPD) evaluated thrombovascular events. An increased risk of thrombovascular events was observed in all but two meta-analyses (relative risks (RRs) ranging from 1.57 to 1.69). However, potential reporting and publication bias as well as detection bias call for a cautious interpretation of these results. Survival and mortality were evaluated in 18 meta-analyses, with the observed effect changing over time. While meta-analyses on studies conducted before 2002 showed beneficial effects of ESAs on survival, contrary results, i.e. worsened survival, was seen in meta-analyses including more recent studies. DISCUSSION The results from several meta-analyses show that ESAs in cancer patients reduce the risk for red blood cell transfusions and increase the risk for thrombovascular events and mortality. The effect of ESAs on mortality risk in patients receiving chemotherapy remains unclear. In clinical practice, the benefits and risks of ESAs should be carefully considered and decisions should be made based on each patient's situation and preferences.
Collapse
Affiliation(s)
- Thomy Tonia
- Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
| | | |
Collapse
|
10
|
|
11
|
Kellokumpu-Lehtinen PL, Puistola U, Paija O, Taimela E, Hirvonen O, Raassina S, Riska H. Anaemia: a rare but neglected problem among Finnish patients receiving chemotherapy for solid tumours. Support Care Cancer 2010; 19:149-53. [PMID: 20101415 DOI: 10.1007/s00520-009-0809-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2009] [Accepted: 12/23/2009] [Indexed: 11/28/2022]
Abstract
GOALS OF THE WORK Anaemia is very frequently diagnosed among cancer patients. Use of erythropoietins has proved to be effective in reducing the need of transfusions and enhancing patients' quality of life, but may also have detrimental effects in treating nonanemic asymptomatic patients. We assessed the frequency of anaemia and the frequency with which it was diagnosed and treated in different types of solid tumours treated at outpatient chemotherapy policlinics. MATERIALS AND METHODS During the study period, altogether 733 consecutive subjects received chemotherapy at the five Finnish University Hospitals. Their data were collected. The physician who was responsible for the chemotherapy treatment was unaware of the survey. The response to anaemia (treated or not, the modality of treatment) were established from patients records; 69% were females, mean age was 61 years (range, 24-92). RESULTS The median haemoglobin level was 12.7 g/dL (range, 8.9-15.5 g/dL). About one third of the patients (200/733, 27%) had a value less than 12 g/dL. In only 15% of these cases was there any documentation of response or a possible treatment option for anaemia. On the other hand, only 12% of all patients (N=91) had a haemoglobin value less than 11 g/dL. However, in most of them anaemia had not been considered; in only 25% of cases was an active treatment option selected. CONCLUSIONS According to our survey, anaemia was less common in our patients than in the European Cancer Anaemia Survey. Only a minority of chemotherapy patients receiving their treatments as outpatients would need active treatment for their anaemia.
Collapse
|
12
|
Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102:301-15. [PMID: 20051958 PMCID: PMC2816662 DOI: 10.1038/sj.bjc.6605498] [Citation(s) in RCA: 182] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND: Cancer patients often develop the potentially debilitating condition of anaemia. Numerous controlled studies indicate that erythropoiesis-stimulating agents (ESAs) can raise haemoglobin levels and reduce transfusion requirements in anaemic cancer patients receiving chemotherapy. To evaluate recent safety concerns regarding ESAs, we carried out a meta-analysis of controlled ESA oncology trials to examine whether ESA use affects survival, disease progression and risk of venous-thromboembolic events. METHODS: This meta-analysis included studies from the 2006 Cochrane meta-analysis, studies published/updated since the 2006 Cochrane report, and unpublished trial data from Amgen and Centocor Ortho Biotech. The 60 studies analysed (15 323 patients) were conducted in the settings of chemotherapy/radiochemotherapy, radiotherapy only treatment or anaemia of cancer. Data were summarised using odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: Results indicated that ESA use did not significantly affect mortality (60 studies: OR=1.06; 95% CI: 0.97–1.15) or disease progression (26 studies: OR=1.01; 95% CI: 0.90–1.14), but increased the risk for venous-thromoboembolic events (44 studies: OR=1.48; 95% CI: 1.28–1.72). CONCLUSION: Though this meta-analysis showed no significant effect of ESAs on survival or disease progression, prospectively designed, future randomised clinical trials will further examine the safety and efficacy of ESAs when used according to the revised labelling information.
Collapse
Affiliation(s)
- J Glaspy
- Department of Medicine-Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA 90095-6996 USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. Clin Transl Oncol 2009; 11:727-36. [DOI: 10.1007/s12094-009-0435-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Pirker R. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues. Expert Opin Drug Saf 2009; 8:515-22. [DOI: 10.1517/14740330903158929] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
15
|
Ludwig H, Crawford J, Österborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA. Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia. J Clin Oncol 2009; 27:2838-47. [DOI: 10.1200/jco.2008.19.1130] [Citation(s) in RCA: 111] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Purpose Although numerous clinical trials have demonstrated the efficacy and tolerability of erythropoiesis-stimulating agents (ESAs) in patients with chemotherapy-induced anemia (CIA), results of some recent trials and one meta-analysis have suggested that ESAs may negatively impact survival and/or disease control in patients with cancer. Methods To assess the benefits and risks of ESAs in CIA, we conducted a pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials in 2,122 patients with CIA receiving darbepoetin alfa (DA; n = 1,200) or placebo (n = 912). Results DA did not increase mortality (hazard ratio = 0.97; 95% CI, 0.85 to 1.1) and had no effect on progression-free survival (hazard ratio = 0.93; 95% CI, 0.84 to 1.04) and disease progression (hazard ratio = 0.92; 95% CI, 0.82 to 1.03), but, as expected, increased the risk for thromboembolic events (hazard ratio = 1.57; 95% CI, 1.10 to 2.26). Overall and progression-free survival were not affected by baseline hemoglobin and seemed better in patients who achieved hemoglobin more than 12 or more than 13 g/dL. Transfusions and rates of hemoglobin increase (> 1 g/dL in 14 days; > 2 g/dL in 28 days) owing to transfusions were associated with an increased risk for death and disease progression in both treatment groups; in the absence of transfusions, rates of hemoglobin increase did not appear to increase the risk for adverse outcomes. Compared with placebo, DA significantly reduced the risk of receiving one or more transfusion. Conclusion There seemed to be no association between DA and risk of death or disease progression in this meta-analysis of individual patient data from DA studies conducted in CIA, the approved indication for ESAs in oncology.
Collapse
Affiliation(s)
- Heinz Ludwig
- From the Wilhelminenspital, Department of Medicine I, Center for Oncology and Hematology, Vienna, Austria; Duke University Medical Center, Durham, NC; Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden; Respiratory Oncology Unit, Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Amgen Inc, Thousand Oaks; and University of California, Los Angeles, School of Medicine, Los
| | - Jeffrey Crawford
- From the Wilhelminenspital, Department of Medicine I, Center for Oncology and Hematology, Vienna, Austria; Duke University Medical Center, Durham, NC; Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden; Respiratory Oncology Unit, Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Amgen Inc, Thousand Oaks; and University of California, Los Angeles, School of Medicine, Los
| | - Anders Österborg
- From the Wilhelminenspital, Department of Medicine I, Center for Oncology and Hematology, Vienna, Austria; Duke University Medical Center, Durham, NC; Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden; Respiratory Oncology Unit, Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Amgen Inc, Thousand Oaks; and University of California, Los Angeles, School of Medicine, Los
| | - Johan Vansteenkiste
- From the Wilhelminenspital, Department of Medicine I, Center for Oncology and Hematology, Vienna, Austria; Duke University Medical Center, Durham, NC; Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden; Respiratory Oncology Unit, Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Amgen Inc, Thousand Oaks; and University of California, Los Angeles, School of Medicine, Los
| | - David H. Henry
- From the Wilhelminenspital, Department of Medicine I, Center for Oncology and Hematology, Vienna, Austria; Duke University Medical Center, Durham, NC; Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden; Respiratory Oncology Unit, Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Amgen Inc, Thousand Oaks; and University of California, Los Angeles, School of Medicine, Los
| | - Alex Fleishman
- From the Wilhelminenspital, Department of Medicine I, Center for Oncology and Hematology, Vienna, Austria; Duke University Medical Center, Durham, NC; Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden; Respiratory Oncology Unit, Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Amgen Inc, Thousand Oaks; and University of California, Los Angeles, School of Medicine, Los
| | - Ken Bridges
- From the Wilhelminenspital, Department of Medicine I, Center for Oncology and Hematology, Vienna, Austria; Duke University Medical Center, Durham, NC; Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden; Respiratory Oncology Unit, Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Amgen Inc, Thousand Oaks; and University of California, Los Angeles, School of Medicine, Los
| | - John A. Glaspy
- From the Wilhelminenspital, Department of Medicine I, Center for Oncology and Hematology, Vienna, Austria; Duke University Medical Center, Durham, NC; Departments of Hematology and Oncology, Karolinska University Hospital, Stockholm, Sweden; Respiratory Oncology Unit, Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium; Pennsylvania Oncology Hematology Associates, Philadelphia, PA; Amgen Inc, Thousand Oaks; and University of California, Los Angeles, School of Medicine, Los
| |
Collapse
|
16
|
Wauters I, Vansteenkiste J. Darbepoetin alfa in the treatment of chemotherapy-induced anaemia. Expert Opin Biol Ther 2009; 9:221-30. [PMID: 19236252 DOI: 10.1517/14712590802652280] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Darbepoetin alfa is an erythropoiesis-stimulating agent (ESA), with a longer half-life than previous recombinant human erythropoietins. After its initial development for anaemia due to renal insufficiency, an extensive clinical trial program has defined its role in cancer patients. OBJECTIVE/METHODS Review of the initial registration studies, further development and recent progress, guidelines for use in clinical practice (EORTC, ASCO/ASH), and specific focus on recent safety concerns. RESULTS Darbepoetin alfa significantly decreases the number of red blood cell transfusions in patients with chemotherapy-induced anaemia, and has been shown to improve health-related quality of life in several studies. The prolonged half-life allows a prolonged dosing interval. Administration every three weeks, a suitable schedule to synchronise with day 1 of many chemotherapy regimens, is as efficient as the initially registered weekly administration. Recent data strongly suggest that the addition of intravenous iron improves haemoglobin response rates. The use of these agents in clinical practice has to be according to the guidelines. Recent safety data reported a negative effect on survival when ESAs were used to treat anaemia that was either not chemotherapy related, or when used to maintain high levels of haemoglobin and prevent anaemia. All of these studies were not in accordance with existing guidelines, while safety data from clinical trials using ESAs according to the guidelines remain reassuring. CONCLUSION Darbepoetin alfa has a well defined place in the treatment of chemotherapy-induced anaemia, and is safe when used in line with existing guidelines. Recent safety signals on cancer outcomes in studies not in accordance with these guidelines illustrate the need for further research into the complex interaction between anaemia and tumour hypoxia in cancer patients.
Collapse
Affiliation(s)
- Isabelle Wauters
- Catholic University, University Hospital Gasthuisberg, Respiratory Oncology Unit (Pulmonology) and Leuven Lung Cancer Group, Herestraat 49, B-3000 Leuven, Belgium
| | | |
Collapse
|
17
|
Winquist E, Julian JA, Moore MJ, Nabid A, Sathya J, Wood L, Venner P, Levine M. Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia. J Clin Oncol 2008; 27:644-6. [PMID: 19103725 DOI: 10.1200/jco.2008.20.4966] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Hedenus M, Näsman P, Liwing J. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. J Clin Pharm Ther 2008; 33:365-74. [PMID: 18613854 DOI: 10.1111/j.1365-2710.2008.00924.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
BACKGROUND AND OBJECTIVE Functional iron deficiency is one reason for lack of response to erythropoietin treatment. Concomitant intravenous (IV) iron supplementation has the potential to improve response to erythropoietin, allowing a decrease in erythropoietin dose requirements. In a recent study of anaemic, iron-replete patients with lymphoproliferative malignancies (Leukemia, 21, 2007, 627), the haemoglobin (Hb) increase and response rate were significantly greater in patients receiving epoetin beta with concomitant IV iron compared with patients receiving epoetin beta without IV iron (P < 0.05). The present analysis aimed to investigate whether a combination of epoetin beta and IV iron is cost-effective compared with epoetin beta without IV iron. METHODS This analysis was performed from a Swedish societal perspective as a within-trial evaluation of overall costs (based on differences in drug costs and resource use between groups) and effect (differences in Hb increases) during 16 weeks' treatment with epoetin beta with or without concomitant IV iron. RESULTS AND DISCUSSION There was an improved response to epoetin beta with IV iron therapy and an almost 2-fold greater increase in Hb levels. Overall mean cost per patient in the epoetin beta with IV iron group was euro5558 and in the epoetin beta without IV iron group was euro6228. Thus, treatment with epoetin beta with IV iron resulted in overall cost savings of about 11% compared with epoetin beta without iron, mainly due to reduced erythropoietin dosages. CONCLUSION Epoetin beta with concomitant IV iron in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy resulted in better outcomes at lower cost compared with epoetin beta without iron. This suggests that epoetin beta with IV iron is a dominant therapy from a Swedish perspective.
Collapse
Affiliation(s)
- M Hedenus
- Department of Internal Medicine, Sundsvall Hospital, Sundsvall, Sweden.
| | | | | |
Collapse
|
19
|
Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 2008; 99:14-22. [PMID: 18542079 PMCID: PMC2453026 DOI: 10.1038/sj.bjc.6604408] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Epoetin-β is used to treat patients with metastatic cancer undergoing chemotherapy to alleviate the symptoms of anaemia, reduce the risk of blood transfusions and improve quality of life. This meta-analysis of 12 randomised, controlled studies evaluated the impact of epoetin-β on overall survival, tumour progression and thromboembolic events (TEEs). A total of 2297 patients were included in the analysis (epoetin-β, n=1244; control, n=1053; 65% solid and 35% nonmyeloid haematological malignancies). A prespecified subgroup analysis assessed the effects in patients with a baseline Hb⩽11 g dl−1, corresponding to current European Organisation for Research and Treatment of Cancer (EORTC) guidelines. No statistically significant effect on mortality was observed with epoetin-β vs control, both overall (hazard ratio (HR)=1.13; 95% CI: 0.87, 1.46; P=0.355) and in patients with baseline Hb⩽11 g dl−1 (HR=1.09; 95% CI: 0.80, 1.47; P=0.579). A trend for a beneficial effect on tumour progression was seen overall (HR=0.85; 95% CI: 0.72, 1.01; P=0.072) and in patients with an Hb⩽11 g dl−1 (HR=0.80; 95% CI: 0.65, 0.99; P=0.041). An increased frequency of TEEs was seen with epoetin-β vs control (7 vs 4% of patients); however, TEEs-related mortality was similar in both groups (1% each). The results of this meta-analysis indicate that when used within current EORTC treatment guidelines, epoetin-β has no negative impact on survival, tumour progression or TEEs-related mortality.
Collapse
|
20
|
Spaëth D. Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia. Expert Rev Anticancer Ther 2008; 8:875-85. [PMID: 18533797 DOI: 10.1586/14737140.8.6.875] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies. Recent evidence-based guidelines recommend the once weekly administration of epoetin beta. This once-weekly regimen is generally well tolerated, and studies to date have reported that epoetin beta has a neutral effect on survival of patients with cancer. The once-weekly administration regimen is convenient for the physician and patient alike. Methods to further optimize this treatment are discussed.
Collapse
Affiliation(s)
- Dominique Spaëth
- Oncologie Médicale, Centre d'Oncologie de Gentilly, 2 rue Marie Marvingt, 54100 Nancy, France.
| |
Collapse
|
21
|
Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF. Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide. J Clin Oncol 2008; 26:2342-9. [DOI: 10.1200/jco.2007.15.0748] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose A placebo-controlled, double-blind, randomized, phase III study was conducted in patients with extensive-stage small-cell lung cancer receiving first-line platinum-containing chemotherapy to determine if increasing or maintaining hemoglobin concentration with darbepoetin alfa could increase patient survival. Patients and Methods Darbepoetin alfa (300 μg) or placebo was administered once per week for 4 weeks then every 3 weeks for up to six cycles of chemotherapy (carboplatin plus etoposide or cisplatin plus etoposide) plus 3 weeks after the last dose of chemotherapy. Patients with disease progression were observed until death or until all patients completed their end-of-study visit and 496 deaths had occurred. The two coprimary end points were change in hemoglobin concentration from baseline to the end of the chemotherapy period and overall survival; statistical testing of survival was done if change in hemoglobin was significant at P < .05. Results The study enrolled 600 patients. Patients' hemoglobin levels dropped due to the myelosuppressive chemotherapy; however, treatment with darbepoetin alfa maintained hemoglobin levels significantly higher than placebo (P < .001). There was no statistically significant difference in overall survival between the treatment groups (hazard ratio [HR], 0.93; 95% CI, 0.78 to 1.11; P = .431). As expected, darbepoetin alfa was associated with a higher incidence of thromboembolic events (darbepoetin alfa, 9%; placebo, 5%). The transfusion risk was lower in the darbepoetin versus placebo group (HR, 0.40; 95% CI, 0.29 to 0.55). Conclusion The results of this study did not demonstrate improved survival after treatment with darbepoetin alfa; however, they reinforce the benefit of erythropoiesis-stimulating agents in reducing transfusions and their neutral impact on survival in patients with chemotherapy-induced anemia.
Collapse
Affiliation(s)
- Robert Pirker
- From the Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Regional Lung Disease Centre, Oncology Department, Poznan, Poland; City Hospital Martha-Maria Halle Doelau, Second Medical Department, Halle, Germany; Department of Pneumology and Thoracic Surgery, Third Faculty of Medicine, Charles University, Faculty Hospital Bulovka, and Postgraduate Medical Institute, Prague, Czech Republic; Respiratory Oncology Unit, Department of Pulmonology, University
| | - Rodryg A. Ramlau
- From the Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Regional Lung Disease Centre, Oncology Department, Poznan, Poland; City Hospital Martha-Maria Halle Doelau, Second Medical Department, Halle, Germany; Department of Pneumology and Thoracic Surgery, Third Faculty of Medicine, Charles University, Faculty Hospital Bulovka, and Postgraduate Medical Institute, Prague, Czech Republic; Respiratory Oncology Unit, Department of Pulmonology, University
| | - Wolfgang Schuette
- From the Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Regional Lung Disease Centre, Oncology Department, Poznan, Poland; City Hospital Martha-Maria Halle Doelau, Second Medical Department, Halle, Germany; Department of Pneumology and Thoracic Surgery, Third Faculty of Medicine, Charles University, Faculty Hospital Bulovka, and Postgraduate Medical Institute, Prague, Czech Republic; Respiratory Oncology Unit, Department of Pulmonology, University
| | - Petr Zatloukal
- From the Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Regional Lung Disease Centre, Oncology Department, Poznan, Poland; City Hospital Martha-Maria Halle Doelau, Second Medical Department, Halle, Germany; Department of Pneumology and Thoracic Surgery, Third Faculty of Medicine, Charles University, Faculty Hospital Bulovka, and Postgraduate Medical Institute, Prague, Czech Republic; Respiratory Oncology Unit, Department of Pulmonology, University
| | - Irene Ferreira
- From the Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Regional Lung Disease Centre, Oncology Department, Poznan, Poland; City Hospital Martha-Maria Halle Doelau, Second Medical Department, Halle, Germany; Department of Pneumology and Thoracic Surgery, Third Faculty of Medicine, Charles University, Faculty Hospital Bulovka, and Postgraduate Medical Institute, Prague, Czech Republic; Respiratory Oncology Unit, Department of Pulmonology, University
| | - Tom Lillie
- From the Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Regional Lung Disease Centre, Oncology Department, Poznan, Poland; City Hospital Martha-Maria Halle Doelau, Second Medical Department, Halle, Germany; Department of Pneumology and Thoracic Surgery, Third Faculty of Medicine, Charles University, Faculty Hospital Bulovka, and Postgraduate Medical Institute, Prague, Czech Republic; Respiratory Oncology Unit, Department of Pulmonology, University
| | - Johan F. Vansteenkiste
- From the Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Regional Lung Disease Centre, Oncology Department, Poznan, Poland; City Hospital Martha-Maria Halle Doelau, Second Medical Department, Halle, Germany; Department of Pneumology and Thoracic Surgery, Third Faculty of Medicine, Charles University, Faculty Hospital Bulovka, and Postgraduate Medical Institute, Prague, Czech Republic; Respiratory Oncology Unit, Department of Pulmonology, University
| |
Collapse
|
22
|
Smith RE, Aapro MS, Ludwig H, Pintér T, Šmakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA. Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Oncol 2008; 26:1040-50. [PMID: 18227526 DOI: 10.1200/jco.2007.14.2885] [Citation(s) in RCA: 165] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose The efficacy and safety of darbepoetin alfa (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic chemotherapy or myelosuppressive radiotherapy was evaluated. Patients and Methods Patients with active cancer and anemia not receiving or planning to receive chemotherapy or radiotherapy were enrolled onto a phase III, multicenter, randomized, placebo-controlled study and administered placebo or DA 6.75 μg/kg every 4 weeks (Q4W) for up to 16 weeks with a 2-year follow-up for survival. Patients who completed 16 weeks of treatment could receive the same treatment as randomized Q4W for an additional 16 weeks. The primary end point was all occurrences of transfusions from weeks 5 through 17; safety end points included incidence of adverse events and survival. Results The incidence of transfusions between weeks 5 and 17 was lower in the DA group but was not statistically significantly different from that of placebo. DA was associated with an increased incidence of cardiovascular and thromboembolic events and more deaths during the initial 16-week treatment period. Long-term survival data demonstrated statistically significantly poorer survival in patients treated with DA versus placebo (P = .022). This effect varied by baseline covariates including, sex, tumor type, and geographic region; statistical significance diminished (P = .12) when the analysis was adjusted for baseline imbalances or known prognostic factors. Conclusion DA was not associated with a statistically significant reduction in transfusions. Shorter survival was observed in the DA arm; thus, this study does not support the use of erythropoiesis-stimulating agents in this subset of patients with anemia of cancer.
Collapse
Affiliation(s)
- Robert E. Smith
- From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los Angeles, School of Medicine, Los Angeles, CA; Clinique de Genolier, Genolier, Switzerland; Wilhelminenspital, 1.Medizinische Abteilung mit Onkologie, Vienna, Austria; Petz Aladar County Teaching Hospital, Gyor, Hungary; Ustav Onkologie a Pneumologie Na Plesi, Onkologicke oddeleni, Plesi, Czech Republic; and Institutul Oncologic “Ion Chiricuta,” Cluj-Napoca, Romania
| | - Matti S. Aapro
- From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los Angeles, School of Medicine, Los Angeles, CA; Clinique de Genolier, Genolier, Switzerland; Wilhelminenspital, 1.Medizinische Abteilung mit Onkologie, Vienna, Austria; Petz Aladar County Teaching Hospital, Gyor, Hungary; Ustav Onkologie a Pneumologie Na Plesi, Onkologicke oddeleni, Plesi, Czech Republic; and Institutul Oncologic “Ion Chiricuta,” Cluj-Napoca, Romania
| | - Heinz Ludwig
- From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los Angeles, School of Medicine, Los Angeles, CA; Clinique de Genolier, Genolier, Switzerland; Wilhelminenspital, 1.Medizinische Abteilung mit Onkologie, Vienna, Austria; Petz Aladar County Teaching Hospital, Gyor, Hungary; Ustav Onkologie a Pneumologie Na Plesi, Onkologicke oddeleni, Plesi, Czech Republic; and Institutul Oncologic “Ion Chiricuta,” Cluj-Napoca, Romania
| | - Tamás Pintér
- From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los Angeles, School of Medicine, Los Angeles, CA; Clinique de Genolier, Genolier, Switzerland; Wilhelminenspital, 1.Medizinische Abteilung mit Onkologie, Vienna, Austria; Petz Aladar County Teaching Hospital, Gyor, Hungary; Ustav Onkologie a Pneumologie Na Plesi, Onkologicke oddeleni, Plesi, Czech Republic; and Institutul Oncologic “Ion Chiricuta,” Cluj-Napoca, Romania
| | - Martin Šmakal
- From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los Angeles, School of Medicine, Los Angeles, CA; Clinique de Genolier, Genolier, Switzerland; Wilhelminenspital, 1.Medizinische Abteilung mit Onkologie, Vienna, Austria; Petz Aladar County Teaching Hospital, Gyor, Hungary; Ustav Onkologie a Pneumologie Na Plesi, Onkologicke oddeleni, Plesi, Czech Republic; and Institutul Oncologic “Ion Chiricuta,” Cluj-Napoca, Romania
| | - Tudor E. Ciuleanu
- From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los Angeles, School of Medicine, Los Angeles, CA; Clinique de Genolier, Genolier, Switzerland; Wilhelminenspital, 1.Medizinische Abteilung mit Onkologie, Vienna, Austria; Petz Aladar County Teaching Hospital, Gyor, Hungary; Ustav Onkologie a Pneumologie Na Plesi, Onkologicke oddeleni, Plesi, Czech Republic; and Institutul Oncologic “Ion Chiricuta,” Cluj-Napoca, Romania
| | - Li Chen
- From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los Angeles, School of Medicine, Los Angeles, CA; Clinique de Genolier, Genolier, Switzerland; Wilhelminenspital, 1.Medizinische Abteilung mit Onkologie, Vienna, Austria; Petz Aladar County Teaching Hospital, Gyor, Hungary; Ustav Onkologie a Pneumologie Na Plesi, Onkologicke oddeleni, Plesi, Czech Republic; and Institutul Oncologic “Ion Chiricuta,” Cluj-Napoca, Romania
| | - Tom Lillie
- From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los Angeles, School of Medicine, Los Angeles, CA; Clinique de Genolier, Genolier, Switzerland; Wilhelminenspital, 1.Medizinische Abteilung mit Onkologie, Vienna, Austria; Petz Aladar County Teaching Hospital, Gyor, Hungary; Ustav Onkologie a Pneumologie Na Plesi, Onkologicke oddeleni, Plesi, Czech Republic; and Institutul Oncologic “Ion Chiricuta,” Cluj-Napoca, Romania
| | - John A. Glaspy
- From the South Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of California, Los Angeles, School of Medicine, Los Angeles, CA; Clinique de Genolier, Genolier, Switzerland; Wilhelminenspital, 1.Medizinische Abteilung mit Onkologie, Vienna, Austria; Petz Aladar County Teaching Hospital, Gyor, Hungary; Ustav Onkologie a Pneumologie Na Plesi, Onkologicke oddeleni, Plesi, Czech Republic; and Institutul Oncologic “Ion Chiricuta,” Cluj-Napoca, Romania
| |
Collapse
|
23
|
|
24
|
Ray-Coquard I, Kassab-Chahmi D, Casadevall N, Chastagner P, Marchal C, Marec-Bérard P, Misset JL. Standards, Options: Recommandations pour I’indication des agents stimulant l’érythropoïèse (ASE: époétine alpha, époétine bêta et darbépoétine) dans la prise en charge de l’anémie en cancérologie (mise à jour 2007), rapport abrégé. ONCOLOGIE 2008. [DOI: 10.1007/s10269-008-0832-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU. Effect of Once-Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy: Results of the Breast Cancer—Anemia and the Value of Erythropoietin (BRAVE) Study. J Clin Oncol 2008; 26:592-8. [DOI: 10.1200/jco.2007.11.5378] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose The Breast Cancer—Anemia and the Value of Erythropoietin (BRAVE) study evaluated whether epoetin beta would improve survival in patients with metastatic breast cancer (MBC). Patients and Methods BRAVE was an open-label, randomized, multicenter study in patients with MBC treated with anthracycline- and/or taxane-based chemotherapy. Patients (hemoglobin [Hb] < 12.9 g/dL) were randomly assigned (1:1) to epoetin beta 30,000 U subcutaneously once weekly or control for 24 weeks. The primary efficacy variable was overall survival. Secondary efficacy outcomes included progression-free survival, transfusion- and severe anemia–free survival, Hb response, safety, and quality of life (QoL). Results After 18 months of follow-up, 62 (27%) of 231 patients survived with epoetin beta therapy and 63 (27%) of 232 with control. No difference was detected in overall survival (hazard ratio [HR] = 1.07; 95% CI, 0.87 to 1.33, P = .522) or progression-free survival (HR = 1.07; 95% CI, 0.89 to 1.30, P = .448). There was a statistically significant benefit on transfusion- and severe anemia–free survival compared with control (HR = 0.59; P = .0097). Median Hb level increased with epoetin beta (11.7 g/dL at baseline to 13.3 g/dL at 24 weeks) but did not change with control (11.5 v 11.4 g/dL). Patients receiving epoetin beta experienced more thromboembolic events (TEEs) compared with controls (13% v 6%; P = .012) with no difference in serious TEEs (4% v 3%). Epoetin beta did not significantly improve QoL in this study where patients had a high baseline Hb value. Conclusion In patients with MBC receiving chemotherapy and initial Hb less than 12.9 g/dL, epoetin beta increased Hb. No difference was detected in overall survival. Because of its superiority design, this study cannot, however, exclude clinically important differences in survival with absolute certainty.
Collapse
Affiliation(s)
- Matti Aapro
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - Robert C. Leonard
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - Agustí Barnadas
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - Maurizio Marangolo
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - Michael Untch
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - Nikolaos Malamos
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - José Mayordomo
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - Dietmar Reichert
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - José Luiz Pedrini
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - Lidia Ukarma
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - Armin Scherhag
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| | - Hans-Ulrich Burger
- From the Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier; F. Hoffmann–La Roche Ltd, Basel, Switzerland; Cancer Services and Clinical Haematology, Imperial College, Charing Cross Hospital, London, United Kingdom; Hospital de Sant Pau, Barcelona; Hospital Clinico Universitario de Zaragoza, Zaragoza, Spain; Divisione Oncologia, Ospedale Provinciale Sta Maria delle Croci, Ravenna, Italy; Helios Klinikum, Berlin Buch; Medical Clinic, University Hospital Mannheim, University of
| |
Collapse
|
26
|
Lehoczky O, Pulay T. [About the infrequent thrombotic events during erythropoietin therapy of anemia in ovarian cancer patients treated with chemotherapy]. Orv Hetil 2007; 148:2081-5. [PMID: 17959551 DOI: 10.1556/oh.2007.28155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Thrombotic events are infrequently observed in erythropoietin treatments for the anemia in tumorous patients with chemotherapy. The manufacturers call attention to this possible side effect of all kind of such drugs. AIM To estimate the amount of thrombotic events in erythropoietin administrations during epoetin treatments for ovarian cancer patients treated with antineoplastic drugs. MATERIAL AND METHODS 275 ovarian cancer patients were treated with erythropoietin in the Gynecologic Department at the National Institute of Oncology, Budapest, in the period between 2000 and 2006: 52 of them were given epoetin-alfa, 157 of them epoetin-beta and 66 of the patients received darbepoetin-alfa. Median age of the patients was 60 (ranges 22 and 84) years. RESULTS Thrombotic events were detected in 3 patients out of the 275: one with epoetin-alfa and two times with epoetin-beta treatment (3/275 = 1,1%). No definite causal relationship was confirmed between the thrombotic events and the erythropoietin drugs. CONCLUSION Thrombosis was infrequently monitored among the authors' patients similarly to the literature data.
Collapse
Affiliation(s)
- Ottó Lehoczky
- Országos Onkológiai Intézet Nogyógyászati Osztálya Budapest.
| | | |
Collapse
|
27
|
Tefferi A. Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor? Mayo Clin Proc 2007; 82:1316-8. [PMID: 17976350 DOI: 10.4065/82.11.1316] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
28
|
Scotté F, di Palma M. Les soins de support générateurs d’effets indésirables. Paradigmes à résoudre Primum non nocere... ONCOLOGIE 2007. [DOI: 10.1007/s10269-007-0723-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Ahlqvist-Rastad J, Albertsson M, Bergh J, Birgegård G, Johansson P, Jonsson B, Kjellen E, Påhlman S, Zackrisson B, Osterborg A. Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations. Med Oncol 2007; 24:267-72. [PMID: 17873301 DOI: 10.1007/s12032-007-0037-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2007] [Revised: 11/30/1999] [Accepted: 05/22/2007] [Indexed: 10/23/2022]
Abstract
Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.
Collapse
|